IONIS PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Private, Subsidiary
- Established
- 1989-01-01
- Employees
- 927
- Market Cap
- -
- Website
- http://www.ionis.fr
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04165486
- Locations
- 🇫🇷
CHU de Lyon - Hospices Civils de Lyon-H6pital Pierre Wertheimer, Neurologique HCL, Lyon, France
🇩🇪Klinikum der Universtiatet Muenchen -Campus Grosshadern, Muenchen, Germany
🇬🇧Salford Royal Hospital, Salford, United Kingdom
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 1438
- Registration Number
- NCT04136171
- Locations
- 🇺🇸
Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT04136184
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
🇺🇸Indiana University School of Medicine - Indianapolis, Indianapolis, Indiana, United States
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04083222
- Locations
- 🇺🇸
National Research Institute - Wilshire, Los Angeles, California, United States
🇺🇸Midwest Institute for Clinical Research, Indianapolis, Indiana, United States
🇺🇸Central Alabama Research, Birmingham, Alabama, United States
Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT04059406
- Locations
- 🇬🇷
Aghia Sophia General Children's Hospital, Athens, Attica, Greece
🇦🇺Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Monash Medical Centre, Clayton, Victoria, Australia
A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04030598
- Locations
- 🇺🇸
Bernstein Clinical Research Center, LLC, Cincinnati, Ohio, United States
🇺🇸Medical Research of Arizona, Scottsdale, Arizona, United States
🇺🇸Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04014335
- Locations
- 🇸🇬
IONIS Investigative Site, Singapore, Singapore
Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
- Conditions
- Interventions
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT03967249
- Locations
- 🇵🇱
Mazowiecki Szpital Brodnowski, Warsaw, Poland
🇷🇺Interregional Clinical Diagnostic Center, Kazan, Russian Federation
🇷🇺Federal State Budget Institution "National Medical Research Center of Endocrinology" of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation
Natural History and Functional Status Study of Patients With Lafora Disease
- Conditions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03876522
- Locations
- 🇪🇸
IONIS Investigative Site, Madrid, Spain
GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT03815825
- Locations
- 🇪🇸
IONIS Investigative Site, Zaragoza, Spain